Quantcast

BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors

January 15, 2014

NEW YORK, January 15, 2014 /PRNewswire/ –

BreedIT Corp (OTC: BRDT), through its Israeli subsidiary, BreedIT Ltd., the exclusive
worldwide distributor of highly sophisticated agro-breeding solutions for plant breeders
and researchers, today announced that on January 7, 2014, the Company’s board of directors
appointed chemistry and pharmaceutical industry expert Dr. Ben-Zion Weiner as its new
member of the board.

From 1975 to 2012, Dr. Weiner held executive positions with Teva Pharmaceutical
Industries Ltd (NYSE:TEVA) and its subsidiaries (“Teva”). He was Vice President of Global
Products of Teva from 2005 to 2011 where he was responsible for global Generic and
Innovative Research and Development.

Dr. Weiner was also a Member of the Core Management Committee.

Dr. Weiner holds a B.Sc. Degree in General Chemistry and Biochemistry, graduating with
distinction at the Hebrew University, Jerusalem, a M.Sc. Degree in Organic Chemistry,
graduating with distinction at the Hebrew University of Jerusalem, and a Ph.D. Degree from
the Hebrew University, Jerusalem. Dr. Weiner did his Post-Doctorate studies at Schering
Plough Corporation in Bloomfield, New Jersey, on “Exploratory work of new drugs, research
in organic chemistry, and pharmacology.” Notable accolades include receiving the
Rothschild Prize for Innovation/Export for the development of Copaxone(R) for Multiple
Sclerosis and for the development of alpha D3 for Dialysis and Osteoporosis.

Dr. Weiner commented, “I am pleased with the high potential of BreedIT’s technology.
My pharmaceutical background will allow me to consult and advise how to maximize future
products potential uses, especially in the efforts to pursue opportunities in the Medical
Cannabis field.”

Itschak Shrem, Chairman of BreedIT Corp., stated, “I would like to officially welcome
Dr. Weiner to our board of directors. His qualifications and expertise in the areas of
chemistry, pharmacology and pharmaceutical products will undoubtedly be of significant
value as we explore our potential in medicinal cannabis and other opportunities.”

About BreedIT Corp

BreedIT Corp (OTC: BRDT), through its Israeli subsidiary, BreedIT Ltd., is the
exclusive world wide distributor of highly sophisticated agro-breeding solutions for plant
breeders and researchers. BreedIT’s proven Intelligent Decision Support System (the “IDSS
Software”), which was developed by a team consisting of among the world’s leading breeding
specialists for optimizing the breeding processes, services the plant breeders,
researchers and governmental institutions. BreedIT’s IDSS provides advanced solutions for
generating and disseminating knowledge aimed at assisting breeders to plan, manage and
analyze their breeding data and to perform research activities quickly and effectively.
Founded in 2010, BreedIT has offices in New York, New York and in Rehovot, Israel.

Forward-Looking Statements:

This press release may contain forward-looking statements, including information about
management’s view of the Company’s future expectations, plans and prospects, within the
safe harbor provisions under The Private Securities Litigation Reform Act of 1995 (the
“Act”). In particular, when used in the preceding discussion, the words “believes,”
“expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional
expressions are intended to identify forward-looking statements within the meaning of the
Act, and are subject to the safe harbor created by the Act. Any statements made in this
news release other than those of historical fact, about an action, event or development,
are forward-looking statements. These statements involve known and unknown risks,
uncertainties and other factors, which may cause the results of the Company, its divisions
and concepts to be materially different than those expressed or implied in such
statements. These risk factors and others are included from time to time in documents the
Company files with the Securities and Exchange Commission, including but not limited to,
its Form 10-K, Form 10-Qs and Form 8-Ks. Other unknown or unpredictable factors also could
have material adverse effects on the Company’s future results. The forward-looking
statements included in this press release are made only as of the date hereof. The Company
cannot guarantee future results, levels of activity, performance or achievements.
Accordingly, you should not place undue reliance on these forward-looking statements.
Finally, the Company undertakes no obligation to update these statements after the date of
this release, except as required by law, and also takes no obligation to update or correct
information prepared by third parties that are not paid for by the Company. In evaluating
such statements, prospective investors should review carefully various risks and
uncertainties identified in this release, as actual results may differ materially from
those indicated.* BreedIt Corp’s public filings may be viewed at http://www.sec.gov/
[http://www.sec.gov ].

        Investor Relations:

        Howard Gostfrand
        info@amcapventures.com
        +1-305-918-7000

SOURCE BreedIT Corp


Source: PR Newswire



comments powered by Disqus